\
&
Contact us
\
&
Contact us
Published on | 2 months ago
ProgrammesThe NCP4Missions Toolkit has been introduced to support applicants for EU Missions calls in Horizon Europe. It encompasses various resources designed to aid a better understanding of the missions and the available funding opportunities.
The toolkit offers firstly a document summarising frequent questions asked during the info days of the European Commission, along with details from the FAQ section on the Funding & Tenders Portal. Additionally, factsheets provide insights into social engagement activities from current projects and list open funding opportunities related to the Missions. The Toolkit also provides an experience analysis document and a mapping of the Mission Hubs.
Explore the Toolkit here. More resources will continue to be added throughout the duration of the NCP4Missions project.
NCP4Missions is a networking project of National Contact Points (NCPs) for the five EU Missions. The project aims, among others, to lower the entry barriers for applicants and raise the quality of proposals by offering support to potential Mission applicants, including brokerages, workshops and other digital tools.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
